Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

JOURNAL ARTICLE published 13 May 2022 in Clinical Cancer Research

Authors: Joaquim Bellmunt | Ronald de Wit | Yves Fradet | Miguel A. Climent | Daniel P. Petrylak | Jae-Lyun Lee | Lawrence Fong | Andrea Necchi | Cora N. Sternberg | Peter H. O'Donnell | Thomas Powles | Elizabeth R. Plimack | Dean F. Bajorin | Arjun V. Balar | Daniel Castellano | Toni K. Choueiri | Stephane Culine | Winald Gerritsen | Howard Gurney | David I. Quinn | Jacqueline Vuky | Nicholas J. Vogelzang | Razvan Cristescu | Jared Lunceford | Assieh Saadatpour | Andrey Loboda | Junshui Ma | Mohini Rajasagi | James Luke Godwin | Blanca Homet Moreno | Petros Grivas